

Monia Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1251911/publications.pdf>

Version: 2024-02-01

128
papers

5,875
citations

87888

38
h-index

79698

73
g-index

130
all docs

130
docs citations

130
times ranked

7443
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
2	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	7.2	415
3	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	4.6	319
4	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. <i>Blood</i> , 2007, 110, 4030-4036.	1.4	233
5	Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2004, 89, 215-32.	3.5	199
6	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
7	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2001, 98, 3249-3255.	1.4	197
8	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.	17.0	189
9	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008, 93, 741-752.	3.5	182
10	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , 2013, 39, 2092-2106.	8.2	169
11	Proposed definition of "poor mobilizer"™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	2.4	156
12	Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 424-431.	1.6	134
13	Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 625-633.	1.6	128
14	Consensus conference on the management of tumor lysis syndrome. <i>Haematologica</i> , 2008, 93, 1877-1885.	3.5	125
15	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. <i>Leukemia Research</i> , 2010, 34, 1576-1588.	0.8	112
16	Chronic Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2003, 2003, 200-224.	2.5	101
17	Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. <i>Leukemia and Lymphoma</i> , 2002, 43, 2301-2307.	1.3	90
18	COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. <i>Annals of Hematology</i> , 2020, 99, 1701-1707.	1.8	90

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2001, 114, 78-83.	2.5	85
20	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2â€“Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia. Journal of Clinical Oncology, 2005, 23, 5688-5695.	1.6	81
21	Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. British Journal of Cancer, 1998, 78, 781-787.	6.4	75
22	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 2005, 106, 2849-2853.	1.4	75
23	Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. American Journal of Medicine, 2001, 111, 130-139.	1.5	72
24	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia, 2019, 33, 1996-2005.	7.2	67
25	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2008, 93, 1364-1371.	3.5	66
26	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica, 2009, 94, 550-565.	3.5	66
27	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood, 2018, 132, 547-550.	1.4	61
28	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	1.4	60
29	Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion, 2013, 53, 2340-2352.	1.6	59
30	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
31	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
32	Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis. Clinical Drug Investigation, 2014, 34, 9-17.	2.2	53
33	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Societ� Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion, 2012, 52, 893-905.	1.6	48
34	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	3.5	48
35	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology, 2022, 9, e301-e311.	4.6	46
36	Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. Journal of Internal Medicine, 1998, 244, 217-226.	6.0	44

#	ARTICLE	IF	CITATIONS
37	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 2004, 124, 618-625.	2.5	43
38	Extended Anticoagulation for Prevention of Recurrent Venous Thromboembolism in Carriers of Factor V Leiden. Thrombosis and Haemostasis, 2000, 84, 752-757.	3.4	42
39	Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age. Hum Vaccin, 2007, 3, 14-22.	2.4	41
40	Deciding when to intervene: a Markov decision process approach. International Journal of Medical Informatics, 2000, 60, 237-253.	3.3	40
41	Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. European Journal of Health Economics, 2013, 14, 853-861.	2.8	40
42	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia, 2017, 31, 882-888.	7.2	40
43	Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 815-824.	1.4	39
44	HIF-1 α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
45	Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI). Supportive Care in Cancer, 2013, 21, 413-419.	2.2	35
46	Identification of new BMP6 pro-peptide mutations in patients with iron overload. American Journal of Hematology, 2017, 92, 562-568.	4.1	35
47	Second cancers in MPN: Survival analysis from an international study. American Journal of Hematology, 2020, 95, 295-301.	4.1	34
48	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood, 2020, 136, 763-766.	1.4	33
49	ESMO, ESMOES, ESMO revised guidelines for the management of follicular lymphoma. American Journal of Hematology, 2013, 88, 185-192.	4.1	32
50	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Journal of Thrombosis and Thrombolysis, 2015, 39, 149-154.	2.1	32
51	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 75-85.	0.4	32
52	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica, 2006, 91, 1662-73.	3.5	32
53	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. American Journal of Hematology, 2018, 93, 698-703.	4.1	31
54	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica, 2018, 103, 1209-1217.	3.5	30

#	ARTICLE	IF	CITATIONS
55	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
56	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2005, 90, 1236-57.	3.5	30
57	Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2006, 91, 96-103.	3.5	30
58	Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian national health service. <i>Clinical Therapeutics</i> , 2004, 26, 1546-1561.	2.5	28
59	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	1.8	28
60	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	2.2	26
61	Clinical and Economic Impact of Epoetins in Cancer Care. <i>Pharmacoeconomics</i> , 2004, 22, 1029-1045.	3.3	23
62	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	3.5	23
63	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. <i>Annals of Oncology</i> , 2012, 23, 1825-1832.	1.2	22
64	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	2.5	22
65	Testing for Occult Cancer in Patients with Idiopathic Deep Vein Thrombosis – A Decision Analysis. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1319-1326.	3.4	21
66	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	1.4	18
67	A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 719-725.	2.4	17
68	What reimbursement for coronary revascularization with drug-eluting stents?. <i>European Journal of Health Economics</i> , 2004, 5, 309-316.	2.8	16
69	Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. <i>Internal and Emergency Medicine</i> , 2011, 6, 17-27.	2.0	16
70	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 221-235.	1.4	16
71	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	1.4	16
72	Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 79-81.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment. <i>Infection</i> , 2011, 39, 375-378.	4.7	15
74	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. <i>Annals of Oncology</i> , 2014, 25, 2339-2350.	1.2	15
75	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	14
76	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 789-795.	1.3	13
77	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. <i>Leukemia Research</i> , 2014, 38, 1269-1277.	0.8	13
78	A policy for the disposal of autologous hematopoietic progenitor cells: report from an <sc>I</sc>alian consensus panel. <i>Transfusion</i> , 2014, 54, 2353-2360.	1.6	12
79	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12
80	Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. <i>Leukemia Research</i> , 2019, 81, 88-94.	0.8	11
81	Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 469-480.	1.4	9
82	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	1.7	9
83	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	1.4	9
84	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8
85	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. <i>Blood Advances</i> , 2022, 6, 3870-3874.	5.2	8
86	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.8	7
87	Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Societ� Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di) Tj ETQq1 1 0.784314 rgBT /Overlook	1.9	7
88	Second versus first wave of COVID-19 in patients with MPN. <i>Leukemia</i> , 2022, 36, 897-900.	7.2	7
89	Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates. <i>Drugs and Aging</i> , 2003, 20, 631-642.	2.7	6
90	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.7	6

#	ARTICLE	IF	CITATIONS
91	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. Journal of Clinical Medicine, 2022, 11, 2076.	2.4	6
92	Value of innovation for hematologic malignancies. Journal of Medical Economics, 2016, 19, 487-489.	2.1	5
93	Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Italy. Blood, 2018, 132, 4779-4779.	1.4	5
94	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. Haematologica, 2002, 87, 472-8.	3.5	5
95	Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 549-564.	1.4	3
96	Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 29-38.	1.4	3
97	Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. Blood, 2005, 106, 258-258.	1.4	3
98	Should I Transplant This Patient with Paroxysmal Nocturnal Hemoglobinuria? a Cost-Effectiveness Analysis of Eculizumab Versus Allogeneic Stem Cell Transplant. Blood, 2014, 124, 735-735.	1.4	3
99	Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. Blood, 2015, 126, 3305-3305.	1.4	3
100	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. Cancers, 2022, 14, 207.	3.7	3
101	Screening for factor V Leiden mutation in pregnant women. Lancet, The, 2002, 360, 1518.	13.7	2
102	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. Blood, 2019, 134, 4170-4170.	1.4	2
103	Selecting Æ-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm. Blood, 2019, 134, 972-972.	1.4	2
104	Cost-Effectiveness of Interim PET Response Adapted Therapy In ABVD-Treated, Advanced-Stage Hodgkin Lymphoma. Blood, 2011, 118, 1563-1563.	1.4	2
105	Italian Society of Hematology guidelines for thalassemia and non-invasive iron measurements: author reply. Haematologica, 2009, 94, 295-296.	3.5	2
106	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
107	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies. Journal of Clinical Medicine, 2022, 11, 1826.	2.4	2
108	Drug-eluting stents: from evidence to policy. Expert Review of Medical Devices, 2004, 1, 49-63.	2.8	1

#	ARTICLE	IF	CITATIONS
109	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. <i>Leukemia</i> , 2020, 34, 1208-1209.	7.2	1
110	Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report. <i>European Journal of Haematology</i> , 2020, 105, 505-507.	2.2	1
111	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4279-4279.	1.4	1
112	Clonal Origin of Circulating Endothelial Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2004, 104, 2427-2427.	1.4	1
113	Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Haematology International Journal</i> , 2017, 1, .	0.0	1
114	Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 263-272.	1.8	1
115	Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1868.	2.4	1
116	Regulation of HIF-1 $\hat{\pm}$ in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.4	0
117	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271.	0.4	0
118	Evaluation of Cytokines Mobilizing Hematopoietic Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. <i>Blood</i> , 2004, 104, 2434-2434.	1.4	0
119	Incidence and Clinical Profile of JAK2 V617F Mutation in Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005, 106, 256-256.	1.4	0
120	99mTc-BW250/183 Bone Marrow Immunoscintigraphy Is Correlated to Clinical and Biologic Features of Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2005, 106, 4944-4944.	1.4	0
121	Revealing the Spectrum of Clinical Syndromes in Idiopathic Myelofibrosis by Cluster Analysis: Featuring “Indolent Myelofibrosis”. <i>Blood</i> , 2006, 108, 2685-2685.	1.4	0
122	Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia.. <i>Blood</i> , 2006, 108, 3617-3617.	1.4	0
123	Iron Supplementation Adjunct to Erythropoiesis Stimulating Agents Is Cost Saving for Chemotherapy-Related Anemia in the Era of Biosimilars. <i>Blood</i> , 2014, 124, 2165-2165.	1.4	0
124	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	1.4	0
125	Identification of New BMP6 Pro-Peptide Mutations in Patients with Unexplained Iron-Overload. <i>Blood</i> , 2016, 128, 264-264.	1.4	0
126	HIF-1 $\hat{\pm}$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. Blood, 2019, 134, 3044-3044.	1.4	0
128	Second <i>Versus</i> First Wave of COVID-19 in Patients with MPN. Blood, 2021, 138, 315-315.	1.4	0